Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Symetrian
- Development stage
- Unknown
- Lead developer
- Unigen
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Symetrian (UP360) is a standardized botanical dietary supplement ingredient developed by Unigen, Inc., composed of extracts from *Aloe barbadensis* (Aloe vera) leaf gel, *Poria cocos* mushroom sclerotium, and *Rosmarinus officinalis* (Rosemary) leaf. It is designed to support immune system homeostasis and enhance immune response. The mechanism of action involves the rapid activation of innate and adaptive immune cells, specifically natural killer (NK) cells, natural killer T (NKT) cells, gamma delta T cells, and monocytes, typically observed within 1 to 3 hours of oral intake. Furthermore, Symetrian has been shown to increase the levels of key antioxidant enzymes, including superoxide dismutase (SOD), catalase, and glutathione peroxidase. Clinical evidence supports its use for long-term daily supplementation and as an adjunct to support immune responses following influenza vaccination.
- Brand names
- Symetrian
- Other names
- Aloe vera + Poria cocos + rosemary extract
02
Targets
γδ TCR (T-cell receptor)NeuraminidaseMisfolded SOD1GPX4 (Glutathione peroxidase 4)
Beyond the preview
Go deeper on Symetrian.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Symetrian.